Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy
Patient-reported outcomes demonstrate that reductions in VMS frequency with fezolinetant treatment were associated with improvements in QOL.
Authors
- Petra Stute (ORCID: https://orcid.org/0000-0002-5591-1552)
- Xuegong Wang (ORCID: https://orcid.org/0000-0001-8812-5841)
- Kentaro Miyazaki (ORCID: https://orcid.org/0000-0002-4349-566X)
- Karla Martins (ORCID: https://orcid.org/0000-0002-5306-7124)
- Katrin Schaudig
- Xi Wu (ORCID: https://orcid.org/0000-0001-6572-4155)
- Rossella Elena Nappi (ORCID: https://orcid.org/0000-0003-1713-6396)
- Antonia Morga (ORCID: https://orcid.org/0009-0008-6671-5056)
- Marla Shapiro C M (ORCID: https://orcid.org/0000-0002-4523-2169)
Institutions
- Astellas Pharma (Japan) (JP)
- Universität Hamburg (DE)
- University of Toronto (CA)
- University of Pavia (IT)
- University Hospital of Bern (CH)
- Astellas Pharma (United Kingdom) (GB)
- Astellas Pharma (United States) (US)
Publication Details
- Journal
- Maturitas
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1016/j.maturitas.2024.108159
- Citations
- 5
- Primary Topic
- Menopause: Health Impacts and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.79
Funders
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders